EFFICACY AND SAFETY OF TOPICAL FINASTERIDE 0.5% SOLUTION ONCE DAILY VERSUS TWICE DAILY IN THE TREATMENT OF MALE ANDROGENETIC ALOPECIA
Phase 2
- Conditions
- Male androgenetic alopecia aged 18-60 yearsMale androgenetic alopecia, topical finasteride, videodermoscope
- Registration Number
- TCTR20240816002
- Lead Sponsor
- Faculty of Medicine, Srinakharinwirot University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending (Not yet recruiting)
- Sex
- Male
- Target Recruitment
- 60
Inclusion Criteria
Male androgenetic alopecia aged 18-60 years Norwood-Hamilton classification type III vertex to V
Exclusion Criteria
1. History of male sexual problems
2. Underlying diseases of hepatitis, kidney disease, cardiovascular disease
3. History of depression, or suicidal idea
4. On the treatment of androgenetic alopecia within 6 months
4. Drug allergy to finasteride
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method